FIND YOUR CONSULTANT
JOIN OUR COMMUNITY
FIND YOUR CONSULTANT
JOIN OUR COMMUNITY

Industries > 

Life Sciences > Biotechnology Practice > Ways Of Working And Agile Implementation

Ways Of Working And Agile Implementation

Service Line: Organization

Finding the right consultant should be this easy.

1

Tell us about your project

2

Interview candidates

(We’ll provide bios within 48 hours on average)

3

Select your consultant and start work!

Find a consultant in our Biotechnology Practice

Prefer email? Write to [email protected]

Capability: Ways Of Working And Agile Implementation

The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Biotechnology Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.

1) Client Situation

The client operated within the therapeutics-focused biotech ecosystem and required support with Ways Of Working And Agile Implementation in the context of Biotechnology. Executives across Emerging Therapeutic Biotech (Preclinical), Clinical-Stage Biotech (Phase I–III), Commercial Biotech (Post-Approval), Platform Biotech (Therapeutic Discovery), and Biotech Investors & Incubators asked for an agile operating model—meeting redesign, launch of cross-functional squads in R&D and CMC, OKRs, and collaboration norms—that increased throughput, improved transparency, and reduced cycle time while remaining compliant with GxP and Part 11/Annex 11. The diagnostic surfaced concrete pain points:

  • Decision latency and meeting overload. Calendars were saturated with status meetings; few forums produced clear decisions. Pre-reads were inconsistent, agendas were diffuse, and action owners were unclear. Cycle time from “issue raised” to “decision made” exceeded milestone tolerances (IND/IMPD, PPQ, launch).
  • Work-in-process (WIP) sprawl and handoff friction. R&D and CMC teams had too many parallel workstreams (assay development, method validation, tech transfer, stability pulls), creating context switching and unplanned work. Handoffs between Analytical, MSAT, QA, and CDMOs generated rework and deviation/CAPA backlog.
  • Opaque priorities and weak alignment. There was no single, visible backlog of milestone-critical work; teams were unsure which tasks mattered most to TPP/IND readiness or PPQ. OKRs (Objectives & Key Results) were absent or not linked to program gates.
  • Fragmented toolchain and data lineage. Jira/Azure DevOps/PPM were used inconsistently; ELN/LIMS/MES/eBR and eQMS were not integrated into daily flow. KPI definitions (lead time, touch time, deviation/CAPA cycle time, QC release TAT) varied by function.
  • Quality and regulatory guardrails not embedded in ways of working. Agile ceremonies existed in pockets but conflicted with document control, validation (CSV), and change control; Part 11/Annex 11 evidence and QMS workflows were not mapped to new cadences.
  • External partner orchestration inconsistent. Sponsor–CDMO squads did not exist or lacked shared backlogs and cadences; QTAs/QSAs and SLAs were not reflected in day-to-day flow, increasing queue time and issue aging.
  • Role ambiguity and limited coaching. Product Owner/Scrum Master analogs were missing; Program Leads carried planning, orchestration, and content burden without facilitation support. Teams had minimal training in Kanban/flow, WIP limits, or root-cause/retrospective practice.
  • Value stream waste unmeasured. No value stream mapping (VSM) existed for high-velocity flows (method lifecycle, stability, tech transfer, deviation/CAPA). Touch vs. wait time, queue aging, and rework rates were unknown; little use of control charts or throughput dashboards.

Performance indicators included: elongated method lifecycle and change control cycle times, deviation/CAPA backlogs, frequent meeting reschedules without decisions, rework in tech transfer packages, unstable QC release TAT near IND and PPQ, and board concern about execution predictability and burn tied to inefficiency.

2) Project Objective

The primary objective focused on implementing an agile, GxP-compliant operating system—cross-functional squads, meeting redesign, OKRs, Kanban/flow practices, and dashboards—so R&D and CMC reduced cycle time, improved decision velocity, and increased throughput from idea to IND/PoC/PPQ/launch.

Secondary objectives included:

  • Standing up milestone-focused squads (e.g., IND Readiness, Method Lifecycle, Tech Transfer/PPQ, Stability & Label Claim) with clear charters, backlogs, WIP limits, and cadences.
  • Redesigning the meeting operating system (weekly operating review; squad stand-ups, planning, and retros; DevCom/CRB alignment) with crisp pre-reads and decision memos.
  • Deploying OKRs that tie directly to program gates and CQAs/CPPs (e.g., reduce deviation/CAPA cycle time, cut method transfer lead time, lift QC release throughput).
  • Implementing visual flow (Kanban boards) and value stream metrics (lead time, touch time, queue aging, throughput) across R&D, CMC, QA, and with CDMOs.
  • Integrating agile with QMS and CSV: map ceremonies to controlled document workflows, change control, and Part 11/Annex 11 evidence without compromising compliance.
  • Launching dashboards with a single KPI dictionary (deviation/CAPA cycle time, change control lead time, QC release TAT, PPQ lot readiness, IND Module 3 burn-down) and alert SLAs.
  • Building internal capability via coaching, role guides (Product Owner, Squad Lead, Flow Master), and train-the-trainer to sustain adoption.

3) Methodology and Approach

Workstream 1: Value Stream Mapping (VSM) and Flow Diagnostics

We quantified waste and designed target-state flow with R&D, CMC, QA, Regulatory, and External Manufacturing.

  • Mapped end-to-end flows: method lifecycle (development → robustness → validation/verification → transfer), deviation/CAPA, change control, stability/label claim, tech transfer/PPQ, and QC release.
  • Measured baselines: lead time, touch time, queue aging, % rework, first-pass yield, deviation/CAPA closure time, change control cycle time, and QC release TAT.
  • Identified bottlenecks: document control queues, cross-functional handoffs, CDMO response SLAs, unprioritized parallel work, unclear data ownership in ELN/LIMS/eBR.
  • Defined flow targets and WIP limits per stream; selected pilot value streams tied to near-term milestones (typically IND readiness and method lifecycle).

Workstream 2: Squad Design, Roles, and Backlogs

We launched milestone-centric squads with clear charters and RACIs integrated with governance.

  • Formed cross-functional squads (6–10 people) around outcomes: IND Readiness, Method Lifecycle, Tech Transfer/PPQ, Stability & Label Claim, and Deviation/CAPA Control.
  • Defined roles: Product Owner (Program Lead or CMC Lead) as decision owner; Flow Master (agile coach) as facilitator; Content Owners (Analytical, MSAT, QA, Regulatory) as accountable task leads; Sponsor Liaison for CDMO integration.
  • Built backlog taxonomies: compliance-bound work (controlled docs, validation), milestone deliverables (Module 3 granules, PPQ protocols), and improvement tasks (automation, templates).
  • Set WIP limits and explicit policies (definition of ready/done, acceptance criteria, change control hooks) to avoid overcommitment and rework.

Workstream 3: Cadence and Meeting Operating System Redesign

We replaced status-heavy meetings with a lean cadence focused on decisions and flow.

  • Instituted squad cadences: daily 15-minute stand-ups; weekly planning (Kanban replenishment); biweekly retrospectives; monthly risk reviews aligned to DevCom/Safety/CRB.
  • Created a weekly cross-squad operating review (45–60 minutes) to remove blockers across value streams; used a consent-agenda and issue-based decision memos.
  • Aligned with governance: DevCom handles stage-gates; CRB handles changes; squads feed decision memos and minimum data packages into forums on a set calendar.
  • Standardized pre-reads and decision memo templates (1-page decision with options, risk/benefit, QMS/CSV impacts, cost/runway) to accelerate approvals.

Workstream 4: OKRs and KPI Architecture

We tied daily work to milestones using OKRs and standardized metrics with lineage.

  • Defined company/portfolio OKRs (e.g., “Submit IND by Q4”); cascaded to squad OKRs (e.g., “Reduce method transfer lead time 30%,” “Close 90% of deviations within SLA”).
  • Built a KPI dictionary: lead time, touch time, throughput, queue aging; deviation/CAPA/change control cycle time; QC release TAT; % first-pass PPQ lots; Module 3 burn-down; on-time CDMO responses.
  • Integrated dashboards (Jira/Azure DevOps/PPM with ELN/LIMS/MES/eBR/eQMS) and set alert SLAs; ensured Part 11/Annex 11 data governance and audit trails.

Workstream 5: Kanban Tooling, Visual Management, and Automation

We implemented visual flow and light automation to reduce cycle time.

  • Configured Kanban boards by value stream; established classes of service (regulatory time-bound, expedite, standard) and service-level expectations (SLEs).
  • Automated handoffs: templates for change control initiation, document control routing, and eBR review; integrated CDMO ticketing for joint backlog items.
  • Introduced control charts for key queues; 5-why and fishbone RCA templates embedded in retrospectives for recurring delays.

Workstream 6: Compliance Guardrails and CSV Integration

We integrated agile ceremonies with GxP, QMS, and Part 11/Annex 11 expectations.

  • Mapped “definition of done” to controlled doc approvals, validation sign-offs, and QTA/QSA requirements; embedded change control hooks into backlog items.
  • Documented CSV impacts for tool changes (Jira/Azure DevOps/automation scripts); set audit trail review cadence; aligned SOP updates with new cadences.
  • Aligned with QA: exception handling and deviation/CAPA workflows fit retrospectives and risk reviews; ensured records for audits/inspections.

Workstream 7: Partner (CDMO/CRO) Integration

We extended squads and cadences to partners with clear KPIs and escalation.

  • Launched joint backlogs and stand-ups for tech transfer and QC/stability with CDMOs; aligned SLAs and sampling/testing schedules with QTAs/QSAs.
  • Added partner KPIs to dashboards (on-time-in-full, deviations closure time, change control cycle time, document turnarounds); set escalation ladders tied to governance.

Workstream 8: Coaching, Training, and Change Management

We built internal capability and reinforced behaviors.

  • Delivered role-based training (Product Owner, Flow Master, Content Owner) and foundational sessions on Kanban/lean, VSM, OKRs, facilitation, and RCA.
  • Embedded agile coaches for 8–12 weeks to guide stand-ups, planning, retros, and metric reviews; established a community of practice and train-the-trainer program.
  • Implemented a communications plan (visuals, FAQs, town halls) and a governance health check (decision throughput, action closure, cadence adherence).

4) Data Request

We requested data and artifacts to execute Ways Of Working And Agile Implementation for clients across the therapeutics spectrum:

  • Calendars and forums:
    • Meeting inventory with attendees, frequency, objectives; decision logs and action trackers; stage-gate packs and review cadences.
  • Flow and performance:
    • Cycle-time metrics for method lifecycle, deviation/CAPA, change control, document control, QC release, stability/timepoints; value stream maps (if any); WIP counts by team.
  • Tooling and integrations:
    • Jira/Azure DevOps/PPM configuration; ELN/LIMS/MES/eBR/eQMS interfaces; data lineage/KPI definitions; audit trail and access control evidence (Part 11/Annex 11).
  • Governance and compliance:
    • QMS SOPs for deviation/CAPA/change control; CSV documentation; QTAs/QSAs; inspection history; CAPA backlogs and SLA data.
  • Portfolio/milestones:
    • Program plans and critical paths (IND/IMPD, EoP2/EoP3, PPQ/launch); resource constraints; CDMO slot calendars.
  • People and roles:
    • Org charts; role descriptions; current “scrum master/PO” equivalents; training materials; manager spans/layers.

Common data pitfalls included missing cycle-time metadata, inconsistent KPI definitions, disconnected toolchains (Jira–PPM–ELN/LIMS), lack of decision logs, and SOPs not aligned to faster cadences. We addressed these through a KPI dictionary, integration runbooks, and SOP updates before pilots.

5) Questions for Client

  • Which milestones (IND/IMPD, EoP2/EoP3, PPQ, launch) are most at risk from cycle-time delays today?
  • Where do decisions routinely stall—committee, document control, partner responses—and what SLAs are acceptable?
  • Which value streams should pilot first (method lifecycle, deviation/CAPA, tech transfer/PPQ, stability/label claim), and what success metrics matter most?
  • What boundaries must guard agile practices (GxP, Part 11/Annex 11, change control, document control, data integrity)?
  • What cadence and forum redesigns are permissible (retire, merge, replace); who will own the weekly operating review?
  • Which tools (Jira/Azure DevOps/PPM) are in scope; what CSV posture and integrations are feasible in phase one?
  • How should squads engage CDMOs/CROs (joint backlog, SLAs); what QTA/QSA terms must flow into day-to-day work?
  • What OKRs will we prioritize (e.g., reduce deviation cycle time 30%, cut method transfer lead time 25%, increase first-pass PPQ lots to 90%)?
  • What coaching capacity is available internally; who are pilot Product Owners and Flow Masters?
  • What cultural constraints (meeting norms, risk appetite) could block adoption; what sponsorship and change tactics will work here?

6) Interview Guide for Subject Matter Experts

Head of R&D/Translational

  • Where do experiments or analyses wait the longest (queues, approvals, handoffs)?
  • How do you prioritize between discovery and IND-critical tasks; what would make priorities visible?
  • What cadence would resolve issues faster without compromising scientific rigor?

Head of CMC/Tech Ops/MSAT

  • Which steps in method lifecycle and tech transfer create the most rework; what WIP limits feel realistic?
  • Where do CDMO interactions stall; which SLAs and joint cadences would unblock flow?
  • What metrics best reflect readiness (PPQ, control strategy closure, QC release) for weekly review?

Head of Quality/QA Ops

  • What deviation/CAPA and change control cycle-time targets are realistic; where does evidence lag?
  • How can agile ceremonies map to QMS without bypassing controls; what SOP updates are required?
  • What Part 11/Annex 11 and CSV workflows must be demonstrated in audits with the new cadence?

Regulatory CMC

  • Where does Module 3/2.3 authoring get blocked; what decision lead times are required?
  • How should change control and comparability (Q5E/Q12) synchronize with squad planning?
  • What OKRs would reduce IRs and rework?

Analytical Development/QC

  • Which method robustness/transfer tasks bottleneck; how can Kanban and WIP limits help?
  • What sampling/testing queues are most volatile; what SLEs are acceptable?
  • Which visual metrics (control charts) would improve predictability?

External Manufacturing (CDMO Lead)

  • What joint cadences and backlogs work best; where do QTAs/QSAs not translate into daily flow?
  • What turnaround times are realistic for deviations, method changes, or batch record updates?
  • Which dashboards help manage OTIF and investigation throughput?

IT/CSV and Data Owners

  • What integrations (Jira/Azure DevOps–PPM–ELN/LIMS–eQMS–eBR) are feasible; what validation is needed?
  • How will audit trails, access controls, and backup/restore be demonstrated for agile tooling?
  • What dashboards and alerting can be automated with minimal CSV burden?

PMO/Portfolio Lead

  • Where do program plans diverge from execution reality; how should OKRs and Kanban tie to portfolio dashboards?
  • What decision memo standards and cadences would improve stage-gate throughput?
  • How should cross-squad blockers escalate into DevCom/CRB?

7) Timeline

We executed a 12-week plan with phases and decision gates tailored to Ways Of Working And Agile Implementation within Organization.

  • Weeks 1–2: Diagnostic and VSM
    • Completed meeting inventory and decision log review; ran value stream mapping for two flows (e.g., method lifecycle and deviation/CAPA); baselined cycle-time metrics.
    • Decision Gate A: Selected pilot value streams and squads; approved KPI dictionary and tooling scope.
  • Weeks 3–4: Squad Launch and Cadence Design
    • Staffed squads and defined charters; created backlogs and WIP limits; designed cadences (stand-ups, planning, retros) and weekly operating review; aligned with DevCom/CRB calendars.
    • Decision Gate B: Ratified role assignments (Product Owner, Flow Master), backlog taxonomy, and cadence.
  • Weeks 5–6: OKRs, Kanban, and Tooling
    • Deployed OKRs linked to milestones; configured Kanban boards in Jira/Azure DevOps/PPM; integrated with ELN/LIMS/eQMS where feasible; documented CSV/Part 11 controls.
    • Decision Gate C: Activated dashboards and alerting; approved SOP updates and compliance guardrails.
  • Weeks 7–8: Partner Integration and Meeting Redesign
    • Launched joint backlogs and stand-ups with CDMOs; implemented consent agendas and decision memos; replaced/retired redundant meetings.
    • Decision Gate D: Validated partner SLAs and cadence; confirmed weekly operating review effectiveness.
  • Weeks 9–10: Coaching and Continuous Improvement
    • Embedded coaches; ran retrospectives with RCA; implemented quick wins (template automation, document control batching, sampling schedule smoothing).
    • Decision Gate E: Demonstrated cycle-time reduction against baselines; selected scale-up roadmap.
  • Weeks 11–12: Scale and Handoff
    • Extended practices to additional value streams (stability/label claim, tech transfer/PPQ); finalized training and playbooks; established community of practice and governance health checks.
    • Decision Gate F: Confirmed steady-state adoption; agreed 90–180 day roadmap (deeper integrations, advanced analytics, wider partner rollout).

Critical path items included executive sponsorship for meeting redesign, QA alignment on SOP and compliance guardrails, tool integration/CSV bandwidth, availability of Product Owners/Flow Masters, and CDMO willingness to adopt joint cadences.

8) Deliverables

  • Agile Operating System Playbook
    • Squad model, roles (Product Owner, Flow Master), cadences, backlog standards, WIP policies, decision memos, and compliance guardrails mapped to QMS/CSV.
  • Value Stream Maps and Target-State Designs
    • Current-state and future-state VSM for method lifecycle, deviation/CAPA, tech transfer/PPQ, stability/label claim; bottlenecks, WIP limits, and SLA targets.
  • OKR Tree and KPI Dictionary
    • Cascaded OKRs linked to milestones; KPI definitions and lineage (lead/touch time, throughput, queue aging, deviation/CAPA/CC cycle time, QC release TAT, PPQ lot readiness, Module 3 burn-down).
  • Kanban Boards and Tooling Configurations
    • Jira/Azure DevOps/PPM boards with classes of service, SLEs, automation hooks to ELN/LIMS/eQMS/eBR; CSV/Part 11/Annex 11 documentation.
  • Meeting Operating System and Governance Integration
    • Redesigned forums calendar, consent agendas, decision memo templates, weekly operating review guide; alignment with DevCom/CRB and stage-gate packs.
  • Dashboards and Control-Tower Alerts
    • Role-based dashboards with drill-through; alerts for queue aging, SLA breaches, deviation/CAPA backlog, change control delays, QC release risk; owner SLAs and escalation ladders.
  • Partner Integration Kit
    • Joint backlog templates, SLA definitions, QTA/QSA flow-through checklist, escalation matrix, and QBR templates for CDMOs/CROs.
  • Training and Coaching Materials
    • Role guides (PO/Flow Master/Content Owner), facilitation guides, Kanban/lean primers, RCA toolkits, SOP updates, and train-the-trainer program.
  • Compliance and SOP Update Pack
    • Mapped agile ceremonies to controlled document workflows, change control, and validation; audit trail review cadences; Part 11/Annex 11 evidence templates.
  • Scale-Up Roadmap
    • Plan to extend agile practices across additional value streams and sites; integration milestones; coaching capacity and community of practice schedule.

9) Industry Insights

Industry dynamics informed Ways Of Working And Agile Implementation within Biotechnology and Organization:

  • Flow beats heroics:
    • High-performing biotechs focus on flow efficiency (reduce wait/queue time) over resource utilization; Kanban with WIP limits outperforms meeting-heavy schedules in R&D/CMC contexts.
    • Value stream metrics (lead/touch time, queue aging, first-pass yield) correlate with IND/PPQ predictability and lower burn per milestone.
  • Agile under GxP:
    • Agile and compliance are compatible when “done” includes controlled documents, validation, and change control; Part 11/Annex 11 audit trails must be part of tooling design, not an afterthought.
    • Retrospectives coupled with CRB decisions shorten deviation/CAPA and change control cycle times, improving inspection readiness.
  • Partner-enabled flow:
    • Joint backlogs and cadences with CDMOs/CROs reduce email-driven queues; QTAs/QSAs should specify SLAs that are tracked in shared boards and QBRs.
    • Embedded sponsor leads at CDMOs (QA, tech transfer) improve issue cycle time when integrated into squads with clear RACIs.
  • Data backbone and lineage:
    • Dashboards only drive behavior when KPI lineage and definitions are standardized; control-tower alerts tied to SLAs create accountability and faster course correction.
    • Lightweight integrations (APIs, data lakes) can deliver visibility quickly if CSV/validation is planned upfront.
  • Meeting operating system:
    • Consent agendas, 1-page decision memos, and timed discussions increase decision throughput; “status to read, decisions to discuss” is a useful norm.
    • Weekly operating reviews that clear cross-squad blockers reduce DevCom escalations and protect stage-gate schedules.
  • OKRs and culture:
    • OKRs linked to milestones (IND/PPQ/launch) align efforts and expose trade-offs; public health metrics (e.g., deviation cycle time) build quality culture.
    • Coaching and a train-the-trainer model are essential to sustain behavior change beyond the pilot period.
  • What “good” looks like:
    • Milestone-centric squads with visible backlogs and WIP limits; weekly operating review; DevCom/CRB fed by decision memos and minimum data packages.
    • Standard KPI dictionary and dashboards; joint backlogs and SLAs with CDMOs; SOPs and CSV integrated into ceremonies; measurable reductions in cycle times and backlog aging.
  • Near-term watch points:
    • Tool sprawl and over-automation without CSV planning; start with value streams and minimum integrations.
    • Resistance from compliance functions unless guardrails are co-designed; involve QA/CSV early and encode controls into “definition of done.”
    • WIP relapse as pressure mounts; enforce WIP policies via visible boards, OKRs, and leadership modeling.

Implications for clients we served included enabling Emerging Therapeutic Biotech to accelerate first-in-human by cutting decision and handoff delays; supporting Clinical-Stage Biotech with disciplined flow for method lifecycle, stability, and tech transfer to de-risk pivotal and PPQ; equipping Commercial Biotech with operating rhythms and partner cadences that sustain launch and lifecycle changes; guiding Platform Biotech to standardize squads, OKRs, and flow practices across programs; and giving Biotech Investors & Incubators a governance and operating lens on execution predictability and burn-efficiency.

Selected Capabilities of our Biotechnology Practice

Strategy & Corporate Development

  • Corporate Strategy And Growth Agenda: Define enterprise ambition, where to play and how to win, therapeutic area focus, build-partner-buy choices, and value creation roadmap for biotech platforms and asset-centric companies.
  • Portfolio Strategy And Indication Prioritization: Optimize pipeline across modalities using rNPV (risk-adjusted net present value), Probability of Technical and Regulatory Success, and constraints to prioritize indications, sequencing, and kill/hold decisions.
  • Business Development And Licensing Strategy: Set business development and licensing (BD&L) strategy, target screening, and out-licensing/in-licensing approach; shape deal thesis, valuation, and term sheets to maximize partnering value and optionality.
  • M&A Strategy And Diligence: Develop biotech mergers and acquisitions (M&A) strategy, longlist, shortlist, and theses; lead commercial, pipeline, and synergy diligence with integration blueprint and carve-out or asset-swap options.
  • Capital Allocation And Investor Readiness: Design capital allocation across programs and platforms; craft investor narrative, valuation, and financing strategy (venture, crossover, IPO) to extend runway and reduce cost of capital.

Operations

  • Manufacturing Operations Excellence: Improve yield, OEE, and right-first-time across upstream, downstream, and fill-finish to cut deviations, cycle time, and cost of goods for biologics and advanced therapies.
  • Tech Transfer And Scale-Up Execution: Plan and execute GMP tech transfer and scale-up, aligning control strategy and PPQ readiness to accelerate time-to-quality and de-risk commercial launch for new modalities.
  • Capacity Modeling And Debottlenecking: Model end-to-end capacity and cycle times, identify bottlenecks, and redesign schedules, changeovers, and cleanroom utilization to unlock throughput and defer capital for biotech facilities.
  • QC Release Cycle Time Reduction: Optimize QC labs with sampling rationalization, Laboratory Information Management System (LIMS), method lifecycle management, and scheduling to shorten batch release times and improve on-time-in-full service.
  • External Manufacturing Performance Management: Set governance with external manufacturing partners, KPIs, escalation, and issue resolution to improve on-time-in-full, right-first-time, and tech transfer outcomes while protecting supply.

Supply Chain

  • Integrated Business Planning And Supply Planning: Build integrated business planning with constrained supply planning and multi‑echelon inventory optimization to improve service, inventory turns, and adherence across drug substance and product networks.
  • Supply Network Design And Footprint Strategy: Optimize network of drug substance and drug product sites, distribution centers, and third‑party logistics to balance total landed cost, service, and risk in make‑buy‑location decisions.
  • Cold Chain And Temperature-Controlled Logistics: Design cold chain strategy, packaging, and lane qualification for 2–8°C, frozen, and cryogenic shipments; enable real‑time monitoring and excursion management to reduce spoilage and write‑offs.
  • Supply Risk And Shortage Management: Build multi‑tier risk mapping, dual‑sourcing strategies, and allocation playbooks with scenario planning and control‑tower alerts to prevent stockouts and manage biologics supply disruptions.
  • Cell And Gene Therapy Orchestration: Design vein‑to‑vein supply chain, chain of identity and custody, apheresis slot scheduling, and courier control to cut turnaround time and failure risk for autologous therapies.

Procurement & Strategic Sourcing

  • Category Strategy And Strategic Sourcing: Build category strategies for GMP raw materials, single-use assemblies, primary packaging; execute e-sourcing and negotiations to deliver Cost of Goods Sold (COGS) reduction and resiliency.
  • CDMO/CRO Vendor Selection And Contracting: Structure sourcing of Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs); set Quality Agreements; negotiate capacity, pricing, and protections to de-risk delivery.
  • Should-Cost Modeling And Clean-Sheet Costing: Develop should-cost models for single-use assemblies, chromatography resins, media, vials, and contract services to set target prices and win fact-based negotiations.
  • Supplier Risk And Continuity Planning: Conduct supplier and tier-2 risk assessments for plasmids, viral vectors, resins; secure long-term agreements, dual-source contracts, and indexation clauses to ensure continuity and price stability.
  • Supplier Relationship Management And Governance: Establish segmentation, joint business plans, Quarterly Business Reviews (QBRs), Key Performance Indicators (KPIs), and innovation pipelines to improve on-time-in-full, quality, and access to new technologies.

R&D & CMC

  • CMC Strategy And IND Readiness: Define phase-appropriate CMC strategy, control plans, and dossier-ready packages to accelerate IND (Investigational New Drug) submissions and de-risk early clinical manufacturing.
  • Process Development And Characterization: Design and optimize upstream and downstream processes using Design of Experiments, scale-down models, and process characterization to achieve titer, purity, and robustness targets pre-transfer.
  • Analytical Development And Method Lifecycle: Build potency, purity, identity, and safety assays; qualify and validate methods; design stability programs to enable release, comparability, and control of critical quality attributes (CQAs).
  • Formulation And Drug Product Development: Develop phase-appropriate formulations, excipient strategies, and container-closure systems for biologics, mRNA, and viral vectors to improve stability, usability, and shelf life.
  • Comparability And Post-Change Strategy: Plan comparability protocols, risk assessments, and bridging analytics for process changes, site moves, or scale-up to protect product quality and avoid clinical rework.

Organization

  • Operating Model And Organizational Design: Design stage-appropriate biotech operating model across R&D, CMC, Clinical, Quality, Supply, and Commercial; align structure, decision rights, and governance to accelerate development and launch.
  • Leadership And Governance Effectiveness: Strengthen executive cadence, board interfaces, decision forums, and RACI (Responsible, Accountable, Consulted, Informed) clarity to speed decisions, resolve cross-functional issues, and drive accountability.
  • Talent Strategy And Workforce Planning: Build capability maps, workforce plans, and location strategy for bioinformatics, process development, regulatory, and commercial roles to meet milestones while optimizing cost and flexibility.
  • Ways Of Working And Agile Implementation: Implement agile teams in R&D and CMC, meeting redesign, OKRs (Objectives and Key Results), and collaboration norms to increase throughput, transparency, and reduce cycle time.
  • Scaling From Virtual To Commercial Organization: Plan build-out of Quality, Supply, and Commercial functions; define roles, spans and layers, and shared services to scale efficiently before first launch.

Marketing

  • Brand Strategy And Positioning: Define biotech brand narrative, target segments, value proposition, and messaging architecture to differentiate in rare and specialty indications and drive HCP and patient preference.
  • Omnichannel HCP Engagement And Content Operations: Design omnichannel journeys, modular content, and channel mix across email, rep-triggered, web, and social to increase HCP reach, engagement, and conversion within regulatory constraints.
  • Key Opinion Leader And Community Influencer Strategy: Map and activate key opinion leaders (KOLs), digital opinion leaders; co-create education, publications, and advisory forums to build credibility and accelerate guideline inclusion and adoption.
  • Launch And Prelaunch Excellence: Build evidence-driven launch plans, disease awareness, patient-finding, and HCP activation; sequence milestones, content, and congresses to maximize share of voice and first-year uptake.
  • Marketing Performance And ROI Analytics: Build dashboards, marketing-mix models, and experimentation to attribute impact, optimize spend, and improve return on investment (ROI) across HCP, patient, and digital channels.

Pricing

  • Launch Pricing And Price Corridor Design: Define Wholesale Acquisition Cost (WAC) and ex-US list prices, price corridors, and price-volume curves by indication to balance access, uptake, and lifetime revenue.
  • Gross-To-Net Optimization: Diagnose rebate, chargeback, copay, 340B Drug Pricing Program (340B), Medicaid Best Price leakages; design contracting, accruals, and governance to improve net price and predictability.
  • Outcomes-Based And Innovative Contracting: Structure outcomes-based contracts, annuity payments, and warranties for gene and cell therapies; define metrics, data flows, and risk-sharing to secure access and net revenue.
  • International Reference Pricing And Launch Sequencing: Model cross-border reference rules, parallel trade, and price spillover; optimize country sequencing, tender posture, and corridors to protect global net price.
  • IRA And Price Renegotiation Readiness: Build Inflation Reduction Act (IRA) strategy, revenue risk scenarios, and negotiation playbooks; adjust contracting, launch timing, and portfolio mix to mitigate price erosion.

Sales

  • Field Force Sizing And Territory Design: Optimize field force size, territories, Customer Relationship Management (CRM) call plans, and routing to maximize healthcare professional (HCP) coverage and productivity for biotech specialty therapeutics.
  • Key Account Management Enablement: Establish Key Account Management (KAM) model for Integrated Delivery Networks (IDNs) and centers of excellence with planning, access pull-through, and cross-functional engagement to drive adoption.
  • Incentive Compensation And Sales Performance Management: Design compliant incentive plans, quotas, and scorecards; align to new patient starts, persistency, and access status to drive specialty biotech revenue growth.
  • Specialty Pharmacy And Hub Pull-Through: Orchestrate specialty pharmacy and patient support hub processes to reduce time-to-fill, improve benefits verification, and increase therapy initiation and adherence for complex treatments.
  • Sales Training And Field Readiness: Develop disease-state and clinical selling curricula, objection handling, and certification; equip field teams with compliant materials and tools to accelerate launch uptake and competitive wins.

Finance

  • FP&A And Runway Management: Build integrated cash, P&L, and scenario models; align to milestones and business development (BD) events; enable rolling forecasts to extend runway and optimize burn.
  • Product Costing And COGS Transparency: Establish standard costing, variance tracking, lot-level analytics, and transfer pricing to improve Cost of Goods Sold (COGS) predictability and margin decisions for biologics.
  • Working Capital Optimization: Optimize inventory policies, supplier terms, and collaboration cash schedules; redesign milestone invoicing to improve cash conversion cycle and fund critical programs.
  • Record To Report And Fast Close: Redesign close processes, chart of accounts, and Sarbanes-Oxley (SOX) controls to enable accurate inventory valuation, capitalization, and fast, audit-ready closes.
  • Collaboration And Revenue Recognition Advisory: Interpret Accounting Standards Codification (ASC) 606 for licenses, milestones, and cost-sharing; design policies, accruals, and systems to ensure compliant, audit-ready biotech revenue recognition and disclosures.

AI, Data & Analytics

  • Biotech Data Platform And Governance: Build FAIR, GxP-compliant data platforms with ontologies and master data to unify preclinical, CMC, clinical, and commercial datasets for analytics, interoperability, and data integrity.
  • CMC Digital Twins And Process AI: Develop bioprocess digital twins, multivariate control, and soft sensors to predict critical quality attributes, boost yield, and reduce deviations, cycle time, and cost.
  • Generative AI Copilots For CMC And Quality: Deploy large language models (LLMs) with Retrieval-Augmented Generation (RAG) for authoring, querying, and change-impact analysis; ensure validation, permissions, and audit trails in regulated environments.
  • RWE And Clinical AI For Trial Acceleration: Build real-world evidence pipelines and machine learning for patient finding, eligibility inference, and site selection to accelerate enrollment and improve protocol feasibility.
  • MLOps And Model Risk Management: Establish data pipelines, feature stores, versioning, monitoring, and validation with model risk controls and change management to safely scale AI in GxP settings.

Transformation

GxP Quality & Compliance

  • Quality Management System Design And Maturity Uplift: Design risk-based QMS aligned to ICH Q10; optimize SOPs, governance, roles, and metrics to meet GMP/GLP/GCP expectations and accelerate approvals and batch release.
  • Inspection Readiness And Remediation: Run risk-based inspection readiness with mock audits, storyboards, SME coaching, and day-in-the-life war rooms; lead remediation and CAPA plans to close FDA/EMA observations.
  • Data Integrity And Computerized Systems Assurance: Assess ALCOA+ data integrity, remediate gaps, and implement risk-based Computer Software Assurance; validate eQMS, LIMS, MES, and analytics with lifecycle controls and audit trails.
  • Deviation CAPA And Change Control Excellence: Redesign deviation, root cause analysis, CAPA effectiveness, and change control workflows; implement analytics and right-first-time behaviors to reduce recurrence, cycle time, and compliance risk.
  • External Partner Quality Oversight And Audits: Establish risk-based oversight for CDMOs, CROs, and suppliers; set Quality Agreements, audit programs, and release-by-exception to strengthen compliance, tech transfer outcomes, and supply reliability.

Program & Portfolio Management

Information Technology

  • IT Strategy And Enterprise Architecture: Define IT strategy, target architecture, and systems roadmap across ERP, MES, LIMS, QMS, CTMS, and EDC to enable scale, compliance, and faster launch readiness.
  • Core Systems Selection And Implementation Readiness: Run vendor selection for ERP, Veeva Vault Quality/Regulatory, MES, LIMS, and CTMS; define requirements, integrations, and implementation governance to de-risk delivery.
  • Cloud And Infrastructure Modernization: Design secure, GxP-ready cloud architecture on AWS or Azure, with network standards and disaster recovery, improving agility, reliability, and cost transparency.
  • Cybersecurity And Identity Management: Build cybersecurity program with risk-based controls, identity and access management, privileged access, and OT segmentation to protect patient data, intellectual property, and manufacturing assets.
  • IT Operating Model And Service Management: Design IT operating model, ITIL processes, and service catalog; establish SLAs, DevSecOps, and vendor management to improve service quality, delivery speed, and compliance.

Regulatory Affairs

  • Global Regulatory Strategy And Agency Engagement: Define IND/CTA-to-BLA/MAA strategy, pursue orphan, Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and PRIME designations, and lead health authority interactions to de-risk development and approvals.
  • Submission Planning And eCTD Readiness: Build submission roadmap, authoring plan, Module 2/3 strategy, vendor/publisher governance, and quality checks to deliver first-cycle, on-time eCTD submissions across regions.
  • Labeling Strategy And Negotiation: Align Target Product Profile, evidence, and claims; lead core data sheet, USPI/SmPC development, negotiation strategies, and CCDS governance to secure competitive labels.
  • Post-Approval Lifecycle And Variations Management: Design regulatory pathways for post-approval changes; prepare supplements and variations, manage commitments, and harmonize dossiers to sustain global compliance and supply continuity.
  • Companion Diagnostic And Combination Product Regulatory Strategy: Define CDx co-development and combination product strategy, classification, and submission pathways; coordinate interactions with FDA device and drug centers to synchronize approvals and enable precision therapy access.

Clinical Development & Operations

  • Protocol Design And Operational Feasibility: Optimize protocol endpoints, eligibility, visit schedules, and assessments using feasibility and real-world data to cut screen failure, patient burden, cost, and cycle time.
  • Country And Site Strategy: Use epidemiology, investigator performance, and startup cycle time data to select countries and sites, set allocations, and build contingency to achieve predictable enrollment.
  • Patient Recruitment And Retention Acceleration: Deploy patient finding, referral networks, decentralized visits, eConsent, diversity plans, and travel support to accelerate enrollment, cut discontinuations, and improve last patient out predictability.
  • Risk Based Quality Management And Monitoring Optimization: Implement risk based quality management per Good Clinical Practice, central monitoring, tolerance limits, and source verification to lower queries, deviations, and monitoring cost.
  • CRO Oversight And Performance Management: Establish sponsor oversight aligned to Good Clinical Practice with KPIs, tolerance limits, issue escalation, and corrective action governance to improve CRO on-time delivery and quality.

Market Access & HEOR

  • Payer Value Proposition And Access Strategy: Define payer value proposition, unmet need, comparators, and access milestones; shape P&T and prior authorization criteria to secure rapid, broad coverage for specialty biologics.
  • Global HTA Strategy And Dossier Development: Develop global value dossier and AMCP dossier; plan NICE, G-BA, SMC, HAS submissions; tailor evidence and narratives to achieve first-cycle HTA approvals.
  • Health Economic Modeling And Evidence Synthesis: Build cost-effectiveness and budget impact models, partitioned survival or Markov; conduct indirect treatment comparisons and network meta-analyses to meet HTA and payer requirements.
  • Real-World Evidence For Value Demonstration: Design RWE strategy including registries, external control arms, and burden-of-illness studies; generate endpoints and PROs supporting HTA, ICER reviews, label expansions, and reimbursement renewals.
  • Coding Coverage And Reimbursement Strategy: Establish coding pathways, HCPCS/CPT/ICD-10 strategies, compendia listings, and site-of-care economics to secure coverage, appropriate payment, and patient affordability across channels.

Connect with the right consultant

Umbrex rapidly connects you with independent professionals who combine top‑tier consulting experience at firms such as McKinsey, Bain, Boston Consulting Group with hands‑on roles.

Find a consultant in our Biotechnology Practice

Prefer email? Write to [email protected]